



## Editorial

# Gynecologic Cancer—A Global Platform for Inclusive Collaboration and Excellence in Gynecologic Oncology

Carlos M. Telleria

Department of Pathology, Faculty of Medicine and Health Sciences, McGill University,  
Montreal, QC H3A 2B4, Canada; carlos.telleria@mcgill.ca

*Gynecologic Cancers*—including ovarian, fallopian tube, endometrial, cervical, vulvar, as well as placental and gestational trophoblastic diseases—remain a major global health burden despite decades of scientific progress. Together, these malignancies account for a substantial proportion of cancer incidence and mortality among women worldwide [1,2], with outcomes varying widely depending on tumor type, stage at diagnosis, and access to effective screening and treatment. While advances in surgery, systemic therapies, and prevention strategies—such as vaccination and screening programs—have improved outcomes in certain settings, many patients continue to be diagnosed at advanced stages, and therapeutic resistance remains a persistent challenge [3]. This reality underscores the need for a focused, agile, and interdisciplinary platform for the dissemination of knowledge. It is in this context that the launch of this new journal is both timely and necessary.

The field of gynecologic oncology has undergone a profound transformation. Once largely defined by histopathological classification, it is now increasingly driven by genomic profiling, characterization of the tumor microenvironment, and biomarker-guided therapies [4]. While novel drug combinations and immune checkpoint inhibitors have created new therapeutic possibilities for selected gynecologic cancers, particularly endometrial and cervical cancers [5,6], they have also introduced complexity into clinical decision-making. Furthermore, disparities in access to care persist across geographic regions, underscoring the importance of inclusive and globally relevant research dissemination [7].

This journal provides a centralized platform for high-quality research that prioritizes the unique biological and translational dimensions of the field. To reflect this evolving landscape, we welcome several manuscript types, including Original Research Articles (comprehensive studies spanning basic, translational, and clinical research), Short Communications (for the rapid dissemination of high-novelty findings), Perspective Articles (to advance conceptual shifts and challenge established paradigms), Reviews (systematic syntheses to guide the field), and Selected Case Reports (offering insights into rare or complex clinical presentations).

We recognize that gynecologic cancer research is a global endeavor. Our International Editorial Board brings together world-class experts to ensure the journal reflects the international scope of these diseases. However, inclusivity is paired with an uncompromising commitment to excellence. We maintain a highly stringent peer-review process grounded in the principles of Scientific Rigor—encompassing methodological accuracy, robust study design, appropriate statistical analysis, reproducibility, adherence to the highest ethical standards, and the generation of meaningful, unbiased findings.

In alignment with this commitment, the journal enforces a strict Data Availability Policy. Authors are required to provide a formal statement specifying where the data



Received: 11 May 2026

Accepted: 8 July 2026

Published: 20 July 2026

Copyright: © 2026 by the author.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

supporting their findings can be accessed. By promoting transparency and fostering data-sharing practices, we enhance reproducibility and accelerate the ability of the scientific community to validate and build upon new discoveries.

The creation of this journal is not merely an academic exercise; it is a commitment to a community. It recognizes that gynecologic oncology is a dynamic and rapidly evolving discipline deserving of a dedicated voice. It provides a forum where Clinicians, Clinician Scientists, Basic Scientists, and Advocates can share insights, challenge assumptions, and collectively advance the field on a global scale.

**Conflicts of Interest:** The author declares no conflicts of interest.

## References

1. Cuello, M.A.; Gomez-Valenzuela, F.; Wichmann, I.; Olawaiye, A.B. Global determinants of gynecologic cancer incidence and mortality: A cluster-based analysis with predictive insights. *Int. J. Gynecol. Obstet.* **2025**, *171*, 147–165. [[CrossRef](#)] [[PubMed](#)]
2. Wei, T.; Li, Y.; Zhang, Z.; Xu, Y.; Huang, H.; Huang, Y.; Li, J.; Gong, Z.; Hu, Z.; Wang, Y.; et al. Global burden, trends, and attributable risk factors of women's cancers with projection to 2050: Results from the GLOBOCAN 2022 and global burden of disease study 2021. *Eur. J. Surg. Oncol.* **2026**, *52*, 111742. [[CrossRef](#)] [[PubMed](#)]
3. Waseem, S.; Zhan, J.; Xiao, X.; Bai, P. Precision oncology in gynecologic cancers: Molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance. *Front. Oncol.* **2026**, *16*, 1785469. [[CrossRef](#)] [[PubMed](#)]
4. McCluggage, W.G. New histopathological and molecular findings in gynecological cancers. *Int. J. Gynecol. Obstet.* **2025**, *171*, 109–119. [[CrossRef](#)] [[PubMed](#)]
5. Yanaihara, N.; Tse, K.Y.; Lee, S.J.; Yoo, J.G.; Wilailak, S. Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives. *Int. J. Gynecol. Obstet.* **2025**, *171*, 166–188. [[CrossRef](#)] [[PubMed](#)]
6. Nasso, C.; Puglisi, S.; Rebuzzi, S.E.; Errigo, V.; Rosa, F.; Chiola, I.; Lazzari, C.; Musizzano, Y.; Venturino, E.; Gastaldo, A.; et al. Immune checkpoint inhibitors in gynecological cancers: A narrative review on the practice-changing trials. *Immunotherapy* **2025**, *17*, 57–66. [[CrossRef](#)] [[PubMed](#)]
7. Ruzindana, K.; Anorlu, R.I. Global disparities in gynecologic cancer outcomes: A call for action. *Int. J. Gynecol. Obstet.* **2025**, *171*, 210–220. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.